Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.

Abstract excerpt

Mutations in the tumor suppressor gene TP53 represent the most frequent genetic difference between tumor cells and normal cells. Here, we have attempted to turn this difference into an advantage for normal cells during therapy. Using the Mdm2 antagonist nutlin-3, we first activated p53 in U2OS and HCT116 cells to induce cell cycle arrest. These arrested cells were found to be resistant to subsequent transient...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cisplatin
• Share to Cytoprotection
• Share to Deoxycytidine